DOCSLIB.ORG

Improving Your Approach to Nasal Obstruction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improving Your Approach to Nasal Obstruction Margaret A. Bayard, MD, Improving your approach MPH, FAAFP; Paul Algra, DO; L. Jared Hyman, DO; Chadwick Donaldson, MD to nasal obstruction Naval Hospital Camp Pendleton, Calif margaret.a.bayard.mil@ The causes are diverse—from rhinitis and rhinosinusitis mail.mil to drugs and structural/mechanical abnormalities. The views expressed in this article are those of the authors and do not Here’s how to provide patients with relief. necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the United States Government. The authors reported no potential conflict of interest asal obstruction is one of the most common reasons relevant to this article. PRACTICE that patients visit their primary care providers.1,2 RECOMMENDATIONS Often described by patients as nasal congestion or the ❯ Consider intranasal N inability to adequately breathe out of one or both nostrils dur- corticosteroids for patients ing the day and/or night, nasal obstruction commonly inter- with nasal polyps, as they are effective at reducing the size feres with a patient’s ability to eat, sleep, and function, thereby of the polyps and associated significantly impacting quality of life. Overlapping presenta- symptoms of obstruction, tions can make discerning the exact cause of nasal obstruction rhinorrhea, and rhinitis. A difficult. ❯ Prescribe intranasal To improve diagnosis and treatment, we review here the corticosteroids for patients evidence-based recommendations for the most common with adenoid hypertrophy. A causes of nasal obstruction: rhinitis, rhinosinusitis (RS), drug- induced nasal obstruction, and mechanical/structural abnor- ❯ Refer patients with chronic malities (TABLE 13-14). refractory rhinosinusitis for functional endoscopic sinus surgery. B Rhinitis/rhinosinusitis: Strength of recommendation (SOR) It all begins with inflammation A Good-quality patient-oriented evidence Sneezing, rhinorrhea, nasal congestion, and nasal itching are B Inconsistent or limited-quality complaints that signal rhinitis, which affects 30 to 60 million patient-oriented evidence people in the United States annually.3 Rhinitis can be allergic, C Consensus, usual practice, opinion, disease-oriented non-allergic, infectious, hormonal, or occupational in nature. evidence, case series All forms of rhinitis share inflammation as the cause of the nasal obstruction. The most common form is allergic rhinitis (AR), which includes seasonal AR and perennial AR. Seasonal AR is typically caused by outdoor allergens and waxes and wanes with pollen seasons. Perennial AR is caused mostly by indoor allergens, such as dust mites, molds, cockroaches, and pet dander; it persists all or most of the year.6 Causes of non- allergic rhinitis (NAR) include environmental irritants such as cigarette smoke, perfume, and car exhaust; medications; and hormonal changes,6 but most causes of NAR are unknown.3,6 While AR can begin at any age, most people develop symp- toms in childhood or as young adults, whereas NAR tends to begin later in life. Nasal itching can help to distinguish AR JFPONLINE.COM VOL 65, NO 12 | DECEMBER 2016 | THE JOURNAL OF FAMILY PRACTICE 889 TABLE 1 Common causes of nasal obstruction—and how to treat them* Condition Characteristics Causes Treatments Comments Allergic rhinitis3,4,6 Sneezing, nasal itching, Extrinsic allergens Allergen avoidance, Often starts in rhinorrhea, nasal intranasal corticosteroids, childhood or young congestion nasal irrigation, adulthood intranasal or oral second-generation anti- histamines, leukotriene receptor antagonists Non-allergic Nasal congestion, post- Unknown causes, Avoid known triggers; Often starts later in life rhinitis3,4,6 nasal drip, rhinorrhea environmental irritants, nasal irrigation, AR medications, hormonal treatments changes Drug-induced Nasal congestion, Use of alpha-adrenergic Discontinue offending rhinitis3,5,6 rhinorrhea nasal spray for >5-7 days, agent NSAIDS, ACE inhibitors, beta-blockers, oral contraceptives, antide- pressants, intranasal cocaine, and methamphetamines† Nasal polyps7-9,14 Nasal congestion, Idiopathic, CF, ARS, Treat overlying ARS/ - If no relief of symp- rhinorrhea NARS, AERD NARS; intranasal toms, consider referral corticosteroids for polypectomy Adenoid Nasal congestion, snoring, Adenoid tissue obstructs Intranasal corticosteroids, If no relief of symp- hypertrophy10-13 mouth breathing, airway leukotriene receptor toms, consider referral recurrent otitis media antagonists for adenoidectomy ACE, angiotensin-converting enzyme; AERD, aspirin-exacerbated respiratory disease; AR, allergic rhinitis; ARS, allergic rhinosinusitis; CF, cystic fibrosis; NARS, non- allergic rhinosinusitis; NSAIDS, nonsteroidal anti-inflammatory drugs. *Nasal obstruction presenting with atypical symptoms and/or not responding to primary treatments should be considered for early referral to Otolaryngology. †The most common agents are listed here; other drug classes may also cause rhinitis. from NAR. NAR symptoms tend to be peren- intranasal glucocorticosteroids (INGCs) are nial and include postnasal drainage. If symp- the most effective monotherapy for AR and toms persist longer than 12 weeks despite NAR and have few adverse effects when used treatment, the condition becomes known as at prescribed doses.3,4 For mild to intermit- chronic rhinosinusitis (CRS). tent symptoms, begin with the maximum dosage of an INGC for the patient’s age and Treatment of rhinitis: proceed with incremental reductions to iden- Tiered and often continuous tify the lowest effective dose.3 If INGCs alone Treatment of AR and NAR is similar and are ineffective, studies have shown that the multitiered beginning with the avoidance of addition of an intranasal second-generation irritants and/or allergens whenever possible, antihistamine can be of some benefit.3,4 In moving on to pharmacotherapy, and, at least fact, an INGC and an intranasal antihista- for AR, ending with allergen immunother- mine—along with saline nasal irrigation—is apy. Treatment is often an ongoing process recommended for both AR and NAR resistant and typically requires continuous therapy as to single therapy.3,6,15 If intranasal antihista- opposed to treatment on an as-needed basis.3 mines are not an option, oral therapy can be It is unnecessary to perform allergy testing initiated. before making a presumed diagnosis of NAR ❚ Start with second-generation antihis- and starting treatment.6 tamines and consider LRAs. For oral therapy, ❚ Intranasal corticosteroids. Currently, start with second-generation antihistamines 890 THE JOURNAL OF FAMILY PRACTICE | DECEMBER 2016 | VOL 65, NO 12 NASAL OBSTRUCTION (loratadine, cetirizine, fexofenadine). First- >65 years of age are uncommon. Rhinitis generation antihistamines (diphenhydr- in this age group is often secondary to cho- amine, hydroxyzine, chlorpheniramine), linergic hyperactivity, alpha-adrenergic although widely available at relatively low hyperactivity, or rhinosinusitis. Given cost, can cause several significant adverse elderly patients’ increased susceptibility to effects including sedation, impaired cogni- the potential adverse central nervous system tive function, and agitation in children.3,4 (CNS) and anticholinergic effects of antihis- Because second-generation antihistamines tamines, non-sedating medications are rec- have fewer adverse effects, they are recom- ommended. Oral decongestants also should mended as first-line therapy when oral anti- be used with caution in this population, not histamine therapy is desired, such as for nasal only because of CNS effects, but also because congestion, sneezing, and itchy, watery eyes. of heart and bladder effects3 (TABLE 218). Of note: A 2014 meta-analysis found that a leukotriene receptor antagonist (LRA) For drug-induced rhinitis, stop (montelukast) had efficacy similar to oral the offending drug and consider an INGC antihistamines for symptom relief in AR, Several types of medications, both oral and and that LRAs may be better suited to night- inhaled, are known to cause rhinitis. The use time symptoms (difficulty falling asleep, of alpha-adrenergic decongestant sprays for nighttime awakenings, congestion on awak- more than 5 to 7 days can induce rebound ening), while antihistamines may provide congestion on withdrawal, known as rhinitis When better relief of daytime symptoms (pruritus, medicamentosa.3 Repeated use of intranasal prescribing rhinorrhea, sneezing).16 Although further cocaine and methamphetamines can also intranasal head-to-head, double-blind randomized result in rebound congestion. Oral medica- corticosteroids controlled trials (RCTs) are needed to con- tions that can result in rhinitis or conges- for allergic firm the results and investigate possible tion include angiotensin-converting enzyme and nonallergic gender differences in symptom response, (ACE) inhibitors, beta-blockers, nonsteroidal rhinitis, begin consider an LRA for first-line therapy in anti-inflammatory drugs (NSAIDS), oral con- with the patients with AR who have predominantly traceptives, and even antidepressants.3 maximum nighttime symptoms. The treatment for drug-induced rhinitis dosage and then is termination of the offending agent. INGCs incrementally What about pregnant women can be used to help decrease inflammation reduce and the elderly? and control symptoms once the offending the amount It is important to consider teratogenicity agent is discontinued. to identify when selecting medications for pregnant the lowest patients, especially during the first trimester.3
Load more

Recommended publications
  • OM-85) on Frequency of Upper Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children with Adenoid Hypertrophy
    STUDY PROTOCOL Effect of Vaxoral® (OM-85) on frequency of upper respiratory tract infections and size of adenoid tissue in preschool children with adenoid hypertrophy Study Product(s) Vaxoral® (OM-85) Indication Recurrent RTIs, adenoid hypertrophy Sponsor Dr Sami Ulus Maternity and Children Research and Training Hospital, Department of Pediatric Allergy and Immunology, Ankara, TURKEY Anticipated Turkey Countries Introduction OM-85 significantly reduces RTIs in children. This effect was proved by many clinical studies and meta-analyses1. A Cochrane meta-analysis first published in 2006 and updated recently (Del- Rio-Navarro 2012) showed that immunostimulants (IS) could reduce acute RTIs (ARTIs) by almost 39% when compared to placebo. Among the different IS, OM-85 showed the most robust evidence with 4 trials of “A quality” according to the Cochrane grading criteria. Pooling six OM-85 studies, the Cochrane review reported a mean number of ARTIs reduction by -1.20 [95% CI: - 1.75, -0.66] and a percentage difference in ARTIs by -35.9% [95% CI: -49.46, -22.35] compared to placebo1. Adenoid hypertrophy (AH) is one of the most important respiratory disease in preschool children2. In normal conditions adenoid tissue enlarges up to 5 years and become smaller afterwards. But in some children who have recurrent URTIs, it keeps growing and this can be associated with complications2. AH may cause recurrent respiratory infections and each infection contributes to enlargement of adenoid tissue thus promoting a vicious cycle. Additionally enlarged adenoids are known to be reservoir for microbes and cause of recurrent or long lasting RTIs3. AH is associated with chronic cough, recurrent and chronic sinusitis, recurrent tonsillitis, recurrent otitis media with effusion, recurrent other respiratory problems such as, nasal obstruction and sleep disturbances, sleep apneas2-3.
    [Show full text]
  • Respiratory Syncytial Virus Bronchiolitis in Children DUSTIN K
    Respiratory Syncytial Virus Bronchiolitis in Children DUSTIN K. SMITH, DO; SAJEEWANE SEALES, MD, MPH; and CAROL BUDZIK, MD Naval Hospital Jacksonville, Jacksonville, Florida Bronchiolitis is a common lower respiratory tract infection in infants and young children, and respiratory syncytial virus (RSV) is the most common cause of this infection. RSV is transmitted through contact with respiratory droplets either directly from an infected person or self-inoculation by contaminated secretions on surfaces. Patients with RSV bronchiolitis usually present with two to four days of upper respiratory tract symptoms such as fever, rhinorrhea, and congestion, followed by lower respiratory tract symptoms such as increasing cough, wheezing, and increased respira- tory effort. In 2014, the American Academy of Pediatrics updated its clinical practice guideline for diagnosis and man- agement of RSV bronchiolitis to minimize unnecessary diagnostic testing and interventions. Bronchiolitis remains a clinical diagnosis, and diagnostic testing is not routinely recommended. Treatment of RSV infection is mainly sup- portive, and modalities such as bronchodilators, epinephrine, corticosteroids, hypertonic saline, and antibiotics are generally not useful. Evidence supports using supplemental oxygen to maintain adequate oxygen saturation; however, continuous pulse oximetry is no longer required. The other mainstay of therapy is intravenous or nasogastric admin- istration of fluids for infants who cannot maintain their hydration status with oral fluid intake. Educating parents on reducing the risk of infection is one of the most important things a physician can do to help prevent RSV infection, especially early in life. Children at risk of severe lower respiratory tract infection should receive immunoprophy- laxis with palivizumab, a humanized monoclonal antibody, in up to five monthly doses.
    [Show full text]
  • Intranasal Ipratropium Bromide Reduced Rhinorrhea and Improved Cold Symptoms
    /:*-..= S Evid Based Med: first published as 10.1136/ebm.1996.1.205 on 1 December 1996. Downloaded from Intranasal ipratropium bromide reduced rhinorrhea and improved cold symptoms Hayden FG, Diamond L, Wood PB, 0.06% in a buffered salt solution (P = 0.003). {This 17% absolute dif- KortsDC, Wecker MT. Effectiveness (2 sprays/nostril [84 u,g] 3 times/d ference in improvement between the and safety of intranasal ipratropium for 4 d) (n = 137), the same nasal ipratropium and placebo groups bromide in common colds. A ran- spray without ipratropium in = 137), means that 6 patients (95% CI, 4 to domized, double-blind, placebo- or no medication (n = 137). No cold 16) would need to be treated with controlled trial. Ann Intern Med. medications other than analgesics ipratropium (rather than placebo) for 1996JullS;12S:89-91. and antitussives were allowed. 4 days to result in improvement for 1 additional patient; the relative risk Main outcome measures improvement was 26%, CI 9% to Objective 47%* }. Rates of nasal dryness (12% To determine whether intxanasal ipra- The main outcome measure was a vs 4%), blood-tinged mucus (17% vs tropium bromide is effective and safe global assessment of overall improve- 4%), and headache (9% vs 2%) were for reducing common cold symptoms. ment (report by patients of being better or much better). Rhinorrhea greater in the ipratropium group than Design was monitored in the clinic hourly in the placebo group. 6-day, randomized, double-blind, for the first 6 hours on day 1 and Conclusion placebo-controlled trial. hourly for 3 hours on day 2.
    [Show full text]
  • Allergic Fungal Airway Disease Rick EM, Woolnough K, Pashley CH, Wardlaw AJ
    REVIEWS Allergic Fungal Airway Disease Rick EM, Woolnough K, Pashley CH, Wardlaw AJ Institute for Lung Health, Department of Infection, Immunity & Inflammation, University of Leicester and Department of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK J Investig Allergol Clin Immunol 2016; Vol. 26(6): 344-354 doi: 10.18176/jiaci.0122 Abstract Fungi are ubiquitous and form their own kingdom. Up to 80 genera of fungi have been linked to type I allergic disease, and yet, commercial reagents to test for sensitization are available for relatively few species. In terms of asthma, it is important to distinguish between species unable to grow at body temperature and those that can (thermotolerant) and thereby have the potential to colonize the respiratory tract. The former, which include the commonly studied Alternaria and Cladosporium genera, can act as aeroallergens whose clinical effects are predictably related to exposure levels. In contrast, thermotolerant species, which include fungi from the Candida, Aspergillus, and Penicillium genera, can cause a persistent allergenic stimulus independent of their airborne concentrations. Moreover, their ability to germinate in the airways provides a more diverse allergenic stimulus, and may result in noninvasive infection, which enhances inflammation. The close association between IgE sensitization to thermotolerant filamentous fungi and fixed airflow obstruction, bronchiectasis, and lung fibrosis suggests a much more tissue-damaging process than that seen with aeroallergens. This review provides an overview of fungal allergens and the patterns of clinical disease associated with exposure. It clarifies the various terminologies associated with fungal allergy in asthma and makes the case for a new term (allergic fungal airway disease) to include all people with asthma at risk of developing lung damage as a result of their fungal allergy.
    [Show full text]
  • Clinical Study Microbiological Profile of Adenoid Hypertrophy Correlates to Clinical Diagnosis in Children
    Hindawi Publishing Corporation BioMed Research International Volume 2013, Article ID 629607, 10 pages http://dx.doi.org/10.1155/2013/629607 Clinical Study Microbiological Profile of Adenoid Hypertrophy Correlates to Clinical Diagnosis in Children Anita Szalmás,1 Zoltán Papp,2 Péter Csomor,2 József Kónya,1 István Sziklai,2 Zoltán Szekanecz,3 and Tamás Karosi2 1 Department of Medical Microbiology, Medical and Health Science Center, University of Debrecen, Nagyerdei Krt. 98, Debrecen 4032, Hungary 2 Department of Otolaryngology and Head and Neck Surgery, Medical and Health Science Center, University of Debrecen, Nagyerdei Krt. 98, Debrecen 4032, Hungary 3 Department of Rheumatology, Medical and Health Science Center, University of Debrecen, Nagyerdei Krt. 98, Debrecen 4032, Hungary Correspondence should be addressed to Tamas´ Karosi; [email protected] Received 24 April 2013; Accepted 23 August 2013 Academic Editor: Ralph Mosges¨ Copyright © 2013 Anita Szalmas´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Adenoid hypertrophy is a common condition in childhood, which may be associated with recurring acute otitis media (RAOM), otitis media with effusion (OME), and obstructive sleeppnea a syndrome (OSAS). These different clinical characteristics have some clinical overlap; however, they might be explained by distinct immunologic and infectious profiles and result in various histopathologic findings of adenoid specimens. Methods. A total of 59 children with adenoid hypertrophy undergoing adenoidectomy were studied. Three series of identical adenoid specimens were processed to hematoxylin-eosin (H.E.) and Gram staining and to respiratory virus specific real-time PCR, respectively.
    [Show full text]
  • Mediastinum and Subcutaneous Emphysema: a Rare Complication of a Common Procedure
    Case Report Brunei Int Med J. 2017; 13 (1): 29-32 Post adenotonsillectomy pneumo- mediastinum and subcutaneous emphysema: A rare complication of a common procedure. Farah Wahida ABD MANAB1,2, Nor Shahida ABDUL MUTALLIB1, Hisham ABDUL RAH- MAN1, Hamidah MAMAT1 1Department of otorhinolaryngology-Head and Neck surgery, Hospital Sultan Abdul Halim, Kedah, Malaysia, 2Department of Otorhinolaryngology, Head and Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia ABSTRACT Cervicofacial and pneumomediastinum subcutaneous emphysema is a very rare complication of adenotonsillectomy procedure. Even though it is a self limiting complication and can be treated conservatively, it can alarming for the patient or patient’s family as well as leading to more seri- ous and fatal consequences occurring from tension pneumomediastinum. We report a case of incidental finding of pneumomediastinum in postadenotonsillectomy patient. He was managed conservatively and made an uneventful recovery. Keywords: tonsillectomy, subcutaneous emphysema, complication INTRODUCTION Case Report Adenotonsillectomy is a common surgical pro- A 12 year old boy was admitted to our Ear, cedure among paediatric age group. It is rela- Nose and Throat (ENT) ward for elective sur- tively a safe procedure with minimal compli- gery of adenotonsillectomy. The indication for cations. Common complications are intraoper- surgery was recurrent attacks of acute tonsil- ative or postoperative haemorrhage, infec- litis. He had underlying Allergic Rhinitis and tion, damaged to soft tissue and surrounding Bronchial Asthma. structure such as teeth, odynophagia and oropharyngeal edema.1 Cervicofacial and Patient was given general anaesthesia with pneumomediastinum subcutaneous emphyse- fentanyl, propofol and cisatracium during in- ma is a very rare complication.
    [Show full text]
  • Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: 3 Prevalence, Severity, Timing and Associated Characteristics 4 5 Marlene M
    Complete Manuscript Click here to access/download;Complete Manuscript;manuscript 042220 v3.docx This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery. 2 Olfactory dysfunction and sinonasal symptomatology in COVID-19: 3 prevalence, severity, timing and associated characteristics 4 5 Marlene M. Speth, MD, MA1, Thirza Singer-Cornelius, MD1, Michael Obere, PhD2, Isabelle 6 Gengler, MD3, Steffi J. Brockmeier, MD1, Ahmad R. Sedaghat, MD, PhD3 7 8 9 1Klinik für Hals-, Nasen-, Ohren- Krankheiten, Hals-und Gesichtschirurgie, Kantonsspital 10 Aarau, Switzerland, 2Institute for Laboratory Medicine, Kantonsspital Aarau, Aarau, 11 Switzerland, 3Department of Otolaryngology—Head and Neck Surgery, University of 12 Cincinnati College of Medicine, Cincinnati, OH, USA. 13 14 15 Funding: MMS and TSC received funding from Kantonsspital Aarau, Department of 16 Otolaryngology, Funded by Research Council KSA 1410.000.128 17 18 Conflicts of Interest: None 19 20 21 Authors’ contributions: 22 MMS: designed and performed study, wrote and revised manuscript, approved final 23 manuscript. 24 TSC: designed and performed study, approved final manuscript. 25 MO: performed study, approved final manuscript. 26 IG: designed study, revised manuscript and approved final manuscript 27 SJB: designed and performed study, revised manuscript and approved final manuscript 28 ARS: conceived, designed and performed study, wrote and revised manuscript, approved 29 final manuscript. 30 31 32 Corresponding Author: 33 Ahmad R. Sedaghat, MD, PhD 34
    [Show full text]
  • Global Strategy for Asthma Management and Prevention, 2019. Available From
    DISTRIBUTE OR COPY NOT DO MATERIAL- COPYRIGHTED ASTHMA MANAGEMENT AND PREVENTION GLOBAL STRATEGY FOR Updated 2019 9 Global Strategy for Asthma Management and Prevention (2019 update) DISTRIBUTE OR COPY NOT DO The reader acknowledges that this reportMATERIAL- is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessing and treating patients, health professionals are strongly advised to use their own professional judgment, and to take into account local or national regulations and guidelines. GINA cannot be held liable or responsible for inappropriate healthcare associated with the use of this document, including any use which is not in accordance with applicable local or national regulations or COPYRIGHTEDguidelines. This document should be cited as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available from: www.ginasthma.org 1 Table of contents Tables and figures ............................................................................................................................................................... 5 Preface ................................................................................................................................................................................. 7 Members of GINA committees (2018) ................................................................................................................................
    [Show full text]
  • Snotty Noses – When Is It Sinusitis? Objectives
    11/2/2019 Snotty Noses – When is it Sinusitis? Uma Ramaswamy, MD Objectives • Identify and medically manage acute rhinosinusitis • Recognize signs/symptoms of pediatric chronic rhinosinusitis (PCRS) • Recognize refractory or complicated sinusitis • When to refer to ENT 1 11/2/2019 https://www.sciencephoto.com/media/728470/view https://www.sciencephoto.com/media/728470/view 2 11/2/2019 Physiology and Function • Humidification • Temperature modification • Filtration of inspired air • Olfaction https://openi.nlm.nih.gov/imgs/512/28/2719610/PMC2719610_1465-9921-10-61-2.png https://hosting.med.upenn.edu/otocme/wp-content/uploads/sites/25/2016/12/pci4-300x183.jpg Pediatric Rhinosinusitis • Inflammation of the nasal cavity and paranasal sinuses Two or more symptoms • Nasal obstruction/congestion • Nasal Discharge – Anterior – Rhinorrhea – Posterior – Post-nasal drip (PND) • Cough • Facial Pain or Pressure • Fever 3 11/2/2019 Contributing Factors • Anatomic Factors • Infectious Agents – Bacterial versus Viral • Biofilms • Adenoids • Allergic Rhinitis • Immunodeficiency • Primary Ciliary Dyskinesia • Cystic Fibrosis Differential Diagnosis of Pediatric Sinusitis • Allergic rhinitis • Chronic invasive fungal sinusitis • Cystic fibrosis • Sinonasal neoplasm • Immotile cilia • Upper respiratory tract infection syndrome/Primary ciliary dyskinesia • Unilateral choanal atresia – Kartagener syndrome (situs • Adenoid hypertrophy inversus, chronic sinusitis, and bronchiectasis) • Nasal foreign body • Odontogenic • Immunodeficiency (immunoglobulin [Ig]A,
    [Show full text]
  • Respiratory Syncytial Virus Infection and Bronchiolitis
    Respiratory Syncytial Virus Infection and Bronchiolitis Giovanni Piedimonte, MD,*† Miriam K. Perez, MD*‡ *Cleveland Clinic Pediatric Institute, Cleveland, OH. †Cleveland Clinic Children’s Hospital for Rehabilitation, The Cleveland Clinic, Cleveland, OH. ‡Department of Community Pediatrics, Independence Family Health Center, Independence, OH. Practice Gaps 1. Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. Although the most effective management of this infection remains supportive care, many patients continue to be managed with therapies that lack the support of scientific evidence. 2. Although the quest for a safe and effective vaccine remains unsuccessful, the more vulnerable patients can be protected with passive prophylaxis. Because of limited clinical benefits and high costs, RSV prophylaxis should be limited to high-risk infants as directed by the most current evidence-based guidelines that, however, are not consistently followed. 3. The acute phase of this infection is often followed by episodes of wheezing that recur for months or years and usually lead to a physician diagnosis of asthma. The phenotype of post-RSV wheezing is different from atopic asthma, yet it is usually managed using the same pharmacologic therapy with often ineffective results. Objectives After reading this article, readers should be able to: 1. Understand the microbiology, epidemiology, pathophysiology, and AUTHOR DISCLOSURE Dr Perez has disclosed clinical manifestations of RSV bronchiolitis in infants and children. fi no nancial relationships relevant to this fi article. Dr Piedimonte has disclosed he 2. Know the scienti c evidence relevant to prophylactic and therapeutic receives research grant NHLBI HL-061007 strategies currently available and recognize the lack of evidence from the National Heart, Lung and Blood concerning several pharmacologic agents commonly used in the Institute of the National Institutes of Health.
    [Show full text]
  • Echocardiographic Characteristics of Nigerian Children with Adenoidal
    nal atio Me sl d n ic a in r e T Animasahun et al., Transl Med (Sunnyvale) 2016, 6:4 Translational Medicine DOI: 10.4172/2161-1025.1000189 ISSN: 2161-1025 Research Article Open Access Echocardiographic Characteristics of Nigerian Children with Adenoidal Hypertrophy: A Multicenter Study Barakat Adeola Animasahun*, Motunrayo O Adekunle, Henry Olusegun Gbelee and Olisamedua Fidelis Njokanma Department of Paediatrics Lagos State University Teaching Hospital Ikeja, Lagos, Nigeria *Corresponding author: Adeola Barakat Animasahun, Lagos State University College of Medicine, Lagos, Nigeria, Tel: +2348055341166; Fax: 2348037250264; E-mail: [email protected] Recieved date: October 27, 2016; Accepted date: November 07, 2016; Published date: November 14, 2016 Copyright: © 2016 Animasahun AB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Adenoidal hypertrophy is a common respiratory disease in childhood with a lethal complication of Cor-Pulmonale. There are few studies on the prevalence of adenoidal hypertrophy in children in Nigeria. The aim of the current study is to document the echocardiographic characteristics of Nigerian Children with adenoidal hypertrophy and compare the findings with those of other children in other parts of the world. Method: The study was prospective, involving subjects from three centers which were; a tertiary hospital, a private hospital and a major cardiology center. Children with clinical and radiological diagnosis of adenoidal hypertrophy had transthoracic echocardiography done by a cardiologist. Results: A total of 1,346 children had echocardiography done within the three years studied period in the centers.
    [Show full text]
  • Subcutaneous Emphysema and Pneumomediastinum After Adenoidectomy; a Rare Complications
    Global Journal of Otolaryngology ISSN 2474-7556 Case Report Glob J Otolaryngol Volume 18 Issue 5 - January 2019 Copyright © All rights are reserved by Mohammed Gamal Aly DOI: 10.19080/GJO.2019.18.556000 Subcutaneous Emphysema and Pneumomediastinum after Adenoidectomy; A Rare Complications Alsaleh Sara, Alabidi Abdulaziz and Mohammed Gamal Aly* Department of Otorhinolaryngology, Head and Neck Surgery, Johns Hopkins Aramco Healthcare, Saudi Arabia Submission: December 26, 2018; Published: January 11, 2019 *Corresponding author: Mohammed Gamal Aly, Department of Otorhinolaryngology, Head and Neck Surgery, Johns Hopkins Aramco Healthcare, Saudi Arabia Abstract Subcutaneous emphysema and pneumomediastinum are an extremely rare complications of adenoidectomy. Although the majority of cases are self-limiting and benign, it may lead to life-threatening complications, such as tension pneumothorax. Symptoms include fever, neck pain, chest pain, dyspnea and odynophagia. We experienced a rare case in which subcutaneous emphysema and pneumomediastinum developed in a healthy 11 years old boy after adenoidectomy only, it was evident by clinical and radiological examinations. This case to our knowledge is the pathogenic mechanisms and treatment options are discussed. first case of subcutaneous emphysema and pneumomediastinum linked to adenoidectomy only in the English literature. Prevalence, possible Keywords: Subcutaneous; Emphysema; Pneumomediastinum; Adenoidectomy Introduction intubation, Mouth gag was applied, and nasal catheter was Adenoidectomy
    [Show full text]